Back to All Combinations
MET Amplification
Poor PrognosisGenes Involved
MET
Treatment Implications
Associated with poor prognosis and anti-EGFR resistance.
Recommended Treatments
Clinical trials
Standard therapy
Treatments to Avoid
Anti-EGFR if amplified
Study References
Resistance studies
Key Statistics
1.50%
Prevalence in CRC
No
Targetable
Clinical Notes
May emerge on anti-EGFR treatment.
Information
Category: Rare Fusions
Evidence Level: Level 3
Last Updated: Dec 7, 2025
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.